Marker Therapeutics (NASDAQ:MRKR) Stock Rating Lowered by Wall Street Zen

Marker Therapeutics (NASDAQ:MRKR) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Sunday.

Several other equities research analysts also recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Wednesday, October 8th. Zacks Research raised shares of Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 18th. Three investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $10.25.

Marker Therapeutics Stock Performance

Marker Therapeutics stock opened at $1.29 on Friday. The company has a 50 day moving average price of $1.00 and a 200 day moving average price of $1.21. Marker Therapeutics has a 52 week low of $0.81 and a 52 week high of $5.95. The firm has a market capitalization of $21.42 million, a price-to-earnings ratio of -1.04 and a beta of 1.47.

Marker Therapeutics (NASDAQ:MRKR) last announced its earnings results on Thursday, November 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.57. The company had revenue of $1.23 million for the quarter, compared to the consensus estimate of $0.72 million. Marker Therapeutics had a negative net margin of 304.56% and a negative return on equity of 92.35%. Equities analysts forecast that Marker Therapeutics will post -0.65 earnings per share for the current fiscal year.

Institutional Trading of Marker Therapeutics

Large investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP acquired a new position in shares of Marker Therapeutics during the 3rd quarter worth $33,000. Virtu Financial LLC bought a new stake in Marker Therapeutics in the third quarter worth $25,000. Finally, Jane Street Group LLC acquired a new position in Marker Therapeutics during the second quarter worth $33,000. 22.39% of the stock is owned by institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.